Notably, treatment with VEGF-A reversed ANGPTL-2 shRNA-induced reductions in LEC tube formation and migration (Figure 4K–4N), implying that ANGPTL2 facilitates VEGF-A-dependent lymphangiogenesis in lung cancer cells. This evidence concerns the gene VEGFA and lung carcinoma.